ECP
CDLX icon

Empyrean Capital Partners’s Cardlytics CDLX Stock Holding History

Empyrean Capital Partners’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-20,178
Closed -$2.95M – 80
2018
Q1 		$2.95M Buy
+20,178
New +$3.41M 0.16% 60

Other funds holding CDLX

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Empyrean Capital Partners's CDLX Position: Q2 2018 in Review

Empyrean Capital Partners sold out of Cardlytics (CDLX) in Q2 2018, closing a stake of 20,178 shares — an estimated $2.95M sold.

Empyrean Capital Partners first reported a position in CDLX in Q1 2018 and held it in 1 quarter. The position peaked at $2.95M in Q1 2018. 53 funds tracked by Wall St. Rank hold CDLX as of Q2 2018.

  • Empyrean Capital Partners reported no remaining Cardlytics position as of Q2 2018 after selling out during the quarter.
  • Empyrean Capital Partners sold 20,178 Cardlytics shares in Q2 2018, an estimated $2.95M.
  • Empyrean Capital Partners first reported a position in Cardlytics in Q1 2018 and held it in 1 quarter.
  • Empyrean Capital Partners's Cardlytics position peaked at $2.95M in Q1 2018.
  • 53 funds tracked by Wall St. Rank held Cardlytics as of Q2 2018.

Based on Empyrean Capital Partners's 13F filing for Q2 2018, filed 14 Aug 2018.